Literature DB >> 3144554

Toxicity and response to high-dose ifosfamide + mesna as salvage therapy for advanced breast cancer.

G G Steger1, C Dittrich, O Schlappack, R Mader, C Herold, W P Brade, A Keller, K Moser.   

Abstract

Twenty-six cycles of high-dose ifosfamide + mesna (HD-IFO + M) were applied to seven female patients with advanced breast cancer refractory to prior treatment, using three different durations of continuous infusion (4, 24, and 48 h) every 3 weeks. To evaluate the most tolerable time schedule, the duration of the infusions was changed periodically in each patient. Toxicity was low in general, but continuous infusion of HD-IFO + M over 24 h appeared to be the best tolerated. One partial response lasting 27 weeks was achieved and four patients achieved stable disease lasting from 9 to 12 weeks.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3144554     DOI: 10.1007/bf00398184

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  12 in total

1.  Studies on the clinical pharmacology and toxicology of isophosphamide (NSC-109724).

Authors:  P J Creaven; L M Allen; M H Cohen; R L Nelson
Journal:  Cancer Treat Rep       Date:  1976-04

2.  Ifosfamide/mesna and hematuria.

Authors:  C B Pratt; M P Goren
Journal:  Cancer Treat Rep       Date:  1987-11

3.  Unexpected toxicity in patients treated with iphosphamide.

Authors:  J J Van Dyk; H C Falkson; A M Van der Merwe; G Falkson
Journal:  Cancer Res       Date:  1972-05       Impact factor: 12.701

4.  Phase II clinical trial of isophosphamide (NSC-109724) in patients with advances breast cancer.

Authors:  D L Ahmann; H F Bisel; R G Hahn
Journal:  Cancer Chemother Rep       Date:  1974 Nov-Dec

Review 5.  Ifosfamide--pharmacology, safety and therapeutic potential.

Authors:  W P Brade; K Herdrich; M Varini
Journal:  Cancer Treat Rev       Date:  1985-03       Impact factor: 12.111

6.  Ifosfamide/mesa and encephalopathy.

Authors:  B M Cantwell; A L Harris
Journal:  Lancet       Date:  1985-03-30       Impact factor: 79.321

7.  High-dose ifosfamide and mesna as continuous infusion over five days--a phase I/II trial.

Authors:  H O Klein; P D Wickramanayake; C Coerper; E Christian; J Pohl; N Brock
Journal:  Cancer Treat Rev       Date:  1983-09       Impact factor: 12.111

8.  Central nervous side effects following ifosfamide monotherapy of advanced renal carcinoma.

Authors:  M E Heim; R Fiene; E Schick; E Wolpert; W Queisser
Journal:  J Cancer Res Clin Oncol       Date:  1981       Impact factor: 4.553

9.  Evaluation of a cooperative clinical study of the cytostatic agent ifosfamide.

Authors:  J Schnitker; N Brock; H Burkert; E Fichtner
Journal:  Arzneimittelforschung       Date:  1976

10.  Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma.

Authors:  B M Bryant; M Jarman; H T Ford; I E Smith
Journal:  Lancet       Date:  1980-09-27       Impact factor: 79.321

View more
  1 in total

1.  Experience of the Belgian Society of Medical Oncology with single-administration 5 g/m2 ifosfamide with mesna as second- or third-line therapy in advanced breast cancer.

Authors:  R Paridaens; C Focan; J Michel; M Piccart; E Salamon; M Beauduin; M T Closon; E Tueni; A Vindevoghel; F Majois
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.